Acorda Therapeutics(US:ACOR)2023-11-13 22:42Financial Performance - INBRIJA U S net revenue reached $8.1 million in Q3 2023, a 4% increase compared to Q3 2022[1,3] - Worldwide INBRIJA net revenue was $9.5 million, a 7% increase, including $1.4 million from ex-U S sales[3] - AMPYRA net revenue was $15.7 million in Q3 2023, a 26% decrease from $21.1 million in Q3 2022[1,3] - FAMPYRA royalty revenues amounted to $2.5 million, a 3% decrease compared to the same quarter in 2022[1,3] - The company reported a GAAP net loss of $8.9 million for Q3 2023, compared to a net loss of $13.9 million in Q3 2022[6] Prescription Trends & Pipeline - New INBRIJA prescription requests increased by 32% in Q3 2023 compared to Q3 2022[2] - New INBRIJA prescription requests increased by 38% in the first three quarters of 2023 versus the same period in 2022[2] - Biopas Laboratories filed for approval of INBRIJA in six Latin American countries[1] Financial Guidance - The company reaffirms INBRIJA U S net revenue guidance to be $34-$38 million for full year 2023[7] - AMPYRA net revenue guidance is reaffirmed to be $65-$70 million for full year 2023[7]